The designed NF-κB inhibitor, DHMEQ, inhibits KISS1R-mediated invasion and increases drug-sensitivity in mouse plasmacytoma SP2/0 cells

YINZHI LIN1,2, KULRAWEE SIDTHIPONG1, JUN MA3, NAOKI KOIDE2, KAZUO UMEZAWA1 and TETSUO KUBOTA4

Departments of 1Molecular Target Medicine and 2Microbiology and Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan; 3Department of Research and Development, Shenzhen Wanhe Pharmaceutical Co., Ltd., Shenzhen, Guangdong 518107, P.R. China; 4Department of Microbiology and Immunology, Tokyo Medical and Dental University Graduate School of Health Care Sciences, Tokyo 113-8510, Japan

Received September 17, 2020; Accepted June 30, 2021

DOI: 10.3892/etm.2021.10526

Abstract. Plasmacytoma is one of the most difficult types of leukemia to treat, and it often invades the bone down to the marrow resulting in the development of multiple myeloma. NF-κB is often constitutively activated, and promotes metastasis and drug resistance in neoplastic cells. The present study assessed the cellular anticancer activity of an NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on mouse plasmacytoma SP2/0 cells. Cellular invasion was measured by Matrigel chamber assay, and apoptosis was assessed by detecting caspase-3 cleavage and by flow cytometric analysis with Annexin V. DHMEQ inhibited constitutively activated NF-κB at nontoxic concentrations. DHMEQ was also shown to inhibit cellular invasion of SP2/0 cells, as well as human myeloma KMS-11 and RPMI-8226 cells. The metastasis PCR array indicated that DHMEQ induced a decrease in KISS1 receptor (KISS1R) expression in SP2/0 cells. Knockdown of KISS1R by small interfering RNA suppressed cellular invasion, suggesting that KISS1R may serve an essential role in the invasion of SP2/0 cells. Furthermore, DHMEQ enhanced cytotoxicity of the anticancer agent melphalan in SP2/0 cells. Notably, DHMEQ inhibited the expression of NF-κB-dependent anti-apoptotic proteins, such as Bcl-XL, FLIP, and Bfl-1. In conclusion, inhibition of constitutively activated NF-κB by DHMEQ may be useful for future anti-metastatic and anticancer strategies for the treatment of plasmacytoma.

Introduction

Plasmacytoma is a malignant disease characterized by plasma cell proliferation in bone, soft tissue, or bone marrow, with an overproduction of monoclonal protein, called M-protein, which causes severe bone pain and bone fractures (1). Accumulation of malignant plasma cells in bone marrow leads to impaired hematopoiesis, recurrent infections, kidney damage, and is associated with a poor prognosis (2). The advanced stage of plasmacytoma is often called multiple myeloma. Homing of plasmacytoma to bone marrow is essential to cell survival and drug resistance (3,4). According to a model described by Butcher and Picker, homing of plasmacytoma cells into the bone marrow is likely to be mediated by a multistep process, including rolling, firm adhesion, and transmigration into the tissue.

Within our present research, DHMEQ was found to inhibit the expression of KISS1 receptor (KISS1R). The KISS1 gene encodes KISS1, a protein that is rapidly processed in serum into smaller but biologically active peptides, called kisspeptins (5). KISS1 and the kisspeptins send the signal via the G-protein coupled receptor KISS1R (also called GPR54) (6). KISS1 was first found to suppress metastasis of malignant melanoma (7). KISS1 was also found to be a metastasis suppressor in many other cancers, such as bladder cancer (8), colorectal cancer (9), ovary cancer (10), and prostate cancer (11). However, besides working as a suppressor of tumorigenesis and metastasis, growing evidence has shown that the KISS1/KISS1R axis plays a cancer-promoting role depending on the cancer type. In triple-negative breast cancer, KISS1R was reported to be overexpressed and to promote drug resistance (12). In addition to playing a promoting role in breast cancer metastasis, KISS1 and KISS1R appear to promote hepatic cell carcinoma (13).

Patients with plasmacytoma often progress to having multiple myeloma with a median survival of 3-5 years (14). Conventional therapies with alkylating agents, such as melphalan, cyclophosphamide, anthracyclines, and corticosteroids, including high-dose therapy followed by autologous transplantation, have shown improved outcomes.
However, such therapies cause numerous side effects (15,16). Moreover, the remission rate remains low and patients often develop resistance to chemotherapy (17).

NF-κB is reported to be constitutively activated in plasmacytoma or multiple myeloma cells (18,19). Recent studies have shown that elevated NF-κB activity promotes growth and drug resistance in plasmacytoma cells, and these effects can be inhibited by blocking NF-κB (20,21). Dehydroxymethylepoxyquinomicin (DHMEQ, Fig. 1A) is a specific inhibitor of NF-κB. It has inhibited various solid tumors and leukemias in animal models without any toxicity (22). DHMEQ was reported to induce apoptosis in multiple myeloma cells and reduce tumor growth in vivo (23). Moreover, DHMEQ enhanced the antitumor effect of fludarabine in chronic lymphocytic leukemia cells (24). In the present study, we researched the effect of DHMEQ on the cellular invasion of chronic lymphocytic leukemia cells (24). In addition, we studied the effect of DHMEQ on sensitivity to melphalan.

In our research we have found that DHMEQ inhibits constitutively activated NF-κB, and inhibits the cellular invasion by suppressing KISSIR expression. It also enhances apoptotic sensitivity to melphalan, possibly by down-regulated expression of anti-apoptotic proteins.

Materials and methods

Chemicals. DHMEQ was synthesized as previously described (25). Melphalan was purchased from Sigma-Aldrich; Merck KGaA. DHMEQ and melphalan were dissolved in dimethyl sulfoxide (DMSO), which was diluted by the medium.

Cell culture. The murine plasmacytoma SP2/0 (RIKEN BioResource Center) and human myeloma KMS-11 (Japanese Collection of Research Bioresources Cell Bank) and RPMI-8226 (Japanese Collection of Research Bioresources Cell Bank) cells were cultured in RPMI-1640 medium (Sigma Chemical) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific), and maintained at 37°C in humidified 95% air, with a 5% CO₂ atmosphere.

NF-κB-DNA binding assay in vitro. SP2/0 cells in complete medium (3x10⁶ cells) were grown in 60-mm dishes. The next day, the nuclear extracts were prepared with Nuclear Extract Kit (Active Motif) according to the instructions of the manufacturer. Briefly, the cells were collected in ice-cold PBS in the presence of phosphatase inhibitors. Then, the cells were suspended in a hypotonic buffer and incubated on ice for 15 min. After incubation, detergent was added and the samples were centrifuged. The supernatants were treated with or without DHMEQ for 2 h. The nuclear extracts were prepared with Nuclear Extract kit (Active Motif), as described previously. Protein contents were determined via the BCA assay. Cell suspensions at a density of 3x10⁵ cells per ml were seeded in a 96-well plate. The next day, cells were treated with the desired concentrations of DHMEQ for 24 h, and at each end-point 2 µl MTT was added to each well and incubated for additional 1 h. For the combined activity study, cells were treated with DHMEQ for 30 min, then melphalan was added at the indicated concentrations and incubated at the indicated times. After incubation, MTT reagent was added to each well and incubated for 1 h. Absorbance was measured at 570 nm with a microplate reader. Cell viability was expressed as a percentage of the control samples.

Inhibition of NF-κB in cultured cells. SP2/0 cells in complete medium (3x10⁶ cells) were grown in 60-mm dishes. The next day, cells were treated with the desired concentrations of DHMEQ for 2 h. The nuclear extracts were prepared with a Nuclear Extract kit (Active Motif), as described previously. Protein contents were determined via the BCA assay. Then, the DNA binding activity of NF-κB in nuclear extracts was measured with the TransAM NF-κB p65 Transcription Factor Assay kit (Active Motif), as described previously.

Matrigel invasion assay. The cells were harvested and washed with PBS. After washing, 3x10⁵ cells were resuspended in 500 µl serum-free medium and treated with different concentrations of DHMEQ. Cells were then transferred to the top of Matrigel-coated invasion chambers (24-well insert; Corning Inc.), and 750 µl of 20% FBS-RPMI-1640 was added to the bottom chamber. After 24 h of incubation, the non-invading cells were removed, and the invading cells that were attached to the bottom were fixed with methanol for 10 min and stained with Diff-Quick solution (Sysmex). Invading cells were photographed under the microscope at x10 magnification and counted.

PCR analysis. SP2/0 cells were treated with DHMEQ for 6 h. Total RNA was extracted from cells using TRizol® reagent (Invitrogen; Thermo Fisher Scientific) following the manufacturer’s instructions. Reverse transcription was carried out at 37°C for 120 min with a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). The cDNA was used for PCR amplification with Tfaq DNA polymerase. The sequence-specific primers were as follows: GAPDH sense, 5'-ACCCAGAGAAGACTGTGGTAGG-3', antisense, 5'-GGATGCAGGGATGATGTTC-3'; Bcl-XL sense 5'-AGTAAACTGCGGCTGCATCG-3', antisense, 5'-GGTGTTGACCTCCACCTCACAC-3'; Bfl-1 sense 5'-GCTCATGCACTTCCCTCC-3', antisense, 5'-GTAGAAGCACTGATGACGGTT-3'; c-FLIP sense 5'-GAAGAAGTGGCACTCGATTAC-3', antisense, 5'-GGAGAACTGCAAAACCAGCT-3'; KISSIR sense, 5'-ATGTCTCCTACAGCAACTCGGC-3', antisense,

1 h. Activated NF-xB binding to the target oligonucleotide was detected by 1 h incubation with a primary antibody specific for the activated form of p65, followed by 1 h incubation with a horseradish peroxidase-conjugated secondary antibody. Then, developing solution was added. Reactions were measured by a colorimetric method at 450 nm, and data were shown as the percent of the positive control signal.

Cell viability assay. Cell viability was evaluated by the MTT assay. Cell suspensions at a density of 3x10⁵ cells per ml were seeded in a 96-well plate. The next day, cells were treated with the desired concentrations of DHMEQ for 24 h, and at each end-point 2 µl MTT was added to each well and incubated for additional 1 h. For the combined activity study, cells were treated with DHMEQ for 30 min, then melphalan was added at the indicated concentrations and incubated at the indicated times. After incubation, MTT reagent was added to each well and incubated for 1 h. Absorbance was measured at 570 nm with a microplate reader. Cell viability was expressed as a percentage of the control samples.
5′-AGAGTGAGCCAGTGGTTC-3′. PCR products were electrophoresed in 2% agarose gels, stained with ethidium bromide, and visualized with a UV illuminator.

**Knockdown by siRNA transfection.** siKISS1R (sc-60748), and control siRNA (sc-37007) were purchased from Santa Cruz Biotechnology Inc. siKISS1R knockdown was performed using Lipofectamine® RNAiMax transfection reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. The efficiency of transfection was determined by mRNA expression.

**Western blotting.** Detection of cleaved caspase-3 induced by DHMEQ and melphalan was performed by western blot analysis. Antibodies used in these experiments were as follows: Rabbit polyclonal antibody for cleaved caspase-3 (Asp175) (Cell Signaling Technology, Inc.), rabbit polyclonal antibody for caspase-3 (Cell Signaling Technology, Inc.), and tubulin (Santa Cruz Biotechnology, Inc.). Cells were lysed in lysis buffer (RIPA). Cell lysates were subjected to electrophoresis on an SDS polyacrylamide gel and transferred onto nitrocellulose membranes. The membranes were blocked with TBS containing 0.05% Tween and 5% nonfat milk at 4°C overnight. Subsequently, they were incubated for 1 h with anti-caspase-3 or anti-tubulin antibodies. The membranes were then incubated for 1 h with peroxidase-labeled anti-rabbit or anti-mouse secondary antibody and developed using an enhanced chemiluminescence system. ImageJ software-based analysis was used to quantify the intensity of the bands obtained by the Western blot assay.

**PCR array.** Total RNA was extracted from SP2/0 cells using RNeasy Mini kit (Qiagen GmbH). RT² First Strand kit (Qiagen, Inc.) was used for reverse transcription. The cDNA was added to the qPCR Master Mix and the aliquot mixture across the Human Tumor Metastasis PCR Array (Qiagen, Inc.). The comparative CT method was used for data analysis.

**Annexin V assay.** The cells were seeded in 24-well culture plates (5x10⁵ cells/well). Next, the cells were incubated with the melphalan (0.3 µg/ml) and/or DHMEQ (10 µg/ml) for 24 h, followed by incubation with annexin V (Ax)-FITC (MBL) and PI (10 µg/ml) at 25°C room temperature for 15 min. Finally, fluorescence intensities were determined by fluorescence-activated cell sorting (FACS) using a FACSCantoII (BD Biosciences).

**Statistical analysis.** All results were expressed as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test was used for statistical analysis by EXCEL software version 2016. P<0.05 was considered to indicate a statistically significant difference.

Figure 1. Inhibition of NF-κB by DHMEQ in SP2/0 cells. (A) Structure of DHMEQ. (B) Inhibition of p65-DNA binding by DHMEQ in vitro. The nuclear extract was prepared from SP2/0 cells. The extract was incubated with DHMEQ for 15 min and the mixture was assayed in xB DNA-coated dishes. DNA binding was detected by labeled p65 antibodies. (C) Effect of DHMEQ on the viability of SP2/0 cells. Cells were treated with DHMEQ for 24 h. Cell viability was determined by MTT assay. (D) Inhibition of cellular NF-κB by DHMEQ. DHMEQ was added to the cultured cells for 2 h, then the nuclear extract was prepared. Nuclear extracts were examined for NF-κB-DNA binding activity. *P<0.05; **P<0.01 vs. untreated control. DHMEQ, dehydroxymethylepoxyquinomicin.
**Results**

Inhibition of NF-κB by DHMEQ. The nuclear fraction of SP2/0 cells was used for NF-κB, including p65. The *in vitro* binding of p65 and κB sequence DNA was inhibited by DHMEQ (Fig. 1A) at 1-10 µg/ml, as shown in Fig. 1B. Next, the effect on viability was studied. DHMEQ did not show prominent cytotoxicity below 10 µg/ml in 24 h, as shown in Fig. 1C. Then, DHMEQ was added to the cultured SP2/0 cells for 2 h. DHMEQ at 1-10 µg/ml inhibited the NF-κB activity in cultured SP2/0 cells (Fig. 1D).

Inhibition of cellular invasion by DHMEQ. Next, we studied the effect of DHMEQ on the cellular invasion of SP2/0 cells using a Matrigel chamber. DHMEQ inhibited the invasion at 1-10 µg/ml dose-dependently, as shown in Fig. 2A. We then studied the effect of DHMEQ on human myeloma cell lines KMS-11 and RPMI-8226. DHMEQ was not toxic at 3 µg/ml, and inhibited cellular invasion below 3 µg/ml in KMS-11 cells (Fig. 2B and C) and in RPMI-8226 cells (Fig. 2D and E). Thus, DHMEQ inhibited cellular invasion in SP2/0 cells and human myeloma KMS-11 and RPMI-8226 cells at nontoxic concentrations.
Inhibition of KISS1R expression by DHMEQ in mouse metastasis PCR array. We employed a mouse metastasis PCR array to study the mechanism of inhibition by DHMEQ. The results of the PCR array are shown in Table SI. Several gene expressions were activated or inhibited by DHMEQ. Among them, we selected KISS1R for further study because its function in cancer progression is not fully understood. We confirmed the effect of DHMEQ on KISS1R expression by independent PCR. DHMEQ inhibited the KISS1R expression as shown in Fig. 3.

Inhibition of cellular invasion by KISS1R knockdown. Next, we prepared KISS1R-knockdown SP2/0 cells using siRNA (Fig. 4A). The knockdown of KISS1R inhibited the invasion, as shown in Fig. 4B. DHMEQ showed no prominent additional effect on invasion (Fig. 4C), which indicates KISS1R is mainly involved in the effect of DHMEQ on inhibition of invasion.

Increase of anticancer drug sensitivity by DHMEQ. Melphalan is an alkylating agent often used for the treatment of plasmacytoma and multiple myeloma. We found that DHMEQ enhanced the cytotoxicity of melphalan in SP2/0 cells (Fig. 5A). Apoptosis was measured by annexin V-FITC/PI and cleaved caspase-3 expression. DHMEQ increased the melphalan-induced apoptosis synergistically (Fig. 5B and C). To understand the mechanism of synergistic apoptosis induction, we studied the effect on NF-κB-dependent apoptosis inhibitory proteins. As shown in Fig. 5D, DHMEQ inhibited the expression of Bcl-XL, Flip, and Bfl-1 in SP2/0 cells. Thus, DHMEQ was shown to increase melphalan sensitivity, possibly by decreasing apoptosis inhibitory proteins.

Discussion

NF-κB is constitutively activated and plays an important role in the suppression of apoptosis in plasmacytoma or multiple melanoma cells (26,27). Over-activation of NF-κB is known to contribute to tumor progression and metastasis (28). Also, drug resistance is a serious problem for plasmacytoma chemotherapy. In the present research, we studied the cellular anti-metastatic activity and the effect on drug sensitivity of an NF-κB inhibitor, DHMEQ.

DHMEQ inhibited cellular invasion by lowering the expression of KISS1R. The KISS1/KISS1R axis has been reported as both a metastasis suppressor and metastasis promoter. Our results indicate that the KISS1/KISS1R axis would act as a metastasis promoter in plasmacytoma cells, and DHMEQ could inhibit the invasion and metastasis via suppression of KISS1R expression. We could not locate a report describing the existence of a κB-site in the promoter of KISS1R. Therefore, it is considered that DHMEQ inhibits KISS1R expression indirectly.

Melpalan is a DNA alkylating agent often used in combination with other anticancer agents or steroids for plasmacytoma patients. For newly diagnosed patients not eligible for a transplant the standard drug combination is melphalan, prednisone, and thalidomide, while an alternate combination is melphalan, prednisone, and bortezomib.
However, the patients receive either therapy often experience drug-mediated side effects, such as neutropenia, thrombocytopenia, and infections (16). Bortezomib, a proteasome inhibitor, inhibits NF-κB by blocking
proteasomal degradation of the inhibitory protein, IκBα. Even though bortezomib shows remarkable anti-tumor activity, it has been associated with possible off-target toxicities and the development of drug resistance (29,30). In the present study, we demonstrate that DHMEQ enhances the cytotoxicity of melphalan on SP2/0 cells. DHMEQ synergistically increases the melphalan-induced apoptosis, possibly by inhibition of antiapoptotic protein expression. Compared to other NF-κB inhibitors, DHMEQ is distinctive by covalently binding to the specific cysteine residue of the Rel family proteins, which is essential for DNA binding (31). It should be noted that DHMEQ alone did not significantly decrease the viability of SP2/0 cells. This finding supports the notion that DHMEQ has no toxicity. Hence, it should be combined with melphalan. On the other hand, we believe that the effect of DHMEQ on bortezomib would not be prominent. This would be because both compounds inhibit the NF-κB activating pathway (32). DHMEQ would also not increase the sensitivity to dexamethasone since this compound is an anti-inflammatory steroid and would affect the NF-κB activity (33).

In conclusion, targeting NF-κB activity is a logical strategy to treat plasmacytoma and prevent progression to multiple myeloma. We also wish to investigate further how DHMEQ inhibits KISS1R expression by searching for the β3 subunit in the promoter region.

Acknowledgements

The authors would like to thank Dr Sivasundaram Karnan (Department of Biochemistry, Aichi Medical University, Nagakute, Japan) for providing us with the human myeloma KMS-11 and RPMI-8226 cell lines.

Funding

The present study was supported in part by JSPS Kakenhi (grant no. 17K01967) and AMED (grant no. JP18fk0310118).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author’s contributions

YL and KS did the majority of experiments. YL and KS confirmed the authenticity of all the raw data. KU, NK and TK designed the experiments. JM prepared DHMEQ. KU, KS and YL prepared the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

Department of Molecular Target Medicine is a fund‐donated laboratory (the authors YL, KS and KU are affiliated with this laboratory). It is supported financially by Shenzhen Wanhe Pharmaceutical Company (the author JM is affiliated with this company), Shenzhen, China, Meiji Seika Pharma, Tokyo, Japan, Fukuyu Medical Corporation, Nishin, Japan, and Bruaine Co., Ltd., Nagoya, Japan.

References

1. Dimopoulos MA, Mouloupolous LA, Maniatis A and Alexanian R: Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96: 2037-2044, 2000.
2. Laubach J, Richardson P and Anderson K: Multiple Myeloma. Annu Rev Med 62: 249-264, 2011.
3. Radbruch A, Muehlinghaus G, Lug er EO, In amine A, Smith KGC, Dörner T and Hiepe F: Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6: 741-750, 2006.
4. Azab AK, Runnells JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, et al: CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113: 4341-4351, 2009.
5. Mendi EJ, Maguire JJ, Kac RE and Davenport AP: Kisspeptins: A multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. Br J Pharmacol 151: 1143-1153, 2007.
6. Kotani M, Dethieux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Poul EL, Brézillon S, Tyldesley R, Suarez-Huerta N, Vandeput F, et al: The metastasis suppressor gene KiSS-1 encodes Kisspeptins, the natural ligands of the orphan g protein-coupled receptor GPR54. J Biol Chem 276: 34631-34636, 2001.
7. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman B and Welch DR: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 88: 1731-1737, 1996.
8. Takeda T, Kikuchi E, Mikami S, Suzuki E, Matsumoto K, Miyajima A, Okada Y and Oya M: Prognostic role of KiSS-1 and possibility of therapeutic modality of metastasis, the final peptide of the KiSs-1 gene, in urothelial carcinoma. Mol Cancer Ther 11: 853-863, 2012.
9. Zhu C, Takasu C, Morino Y, Bando Y, Ikemoto T, Saito Y, Yamada S, Imura S, Arakawa Y and Shimada M: KiSS1 associates with better outcome via inhibiting matrix metalloproteinase-9 in colorectal liver metastasis. Ann Surg Oncol 22: 1516-1523, 2015.
10. Jiang Y, Berk M, Singh LS, Tan H, Yin L, Powell CT and Xu Y: KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase Calpha. Clin Exp Metastasis 22: 369-376, 2005.
11. Wang H, Jones J, Turner T, He QP, Hardy S, Grizzle WE, Welch DR and Yates C: Clinical and biological significance of KiSS1 expression in prostate cancer. Am J Pathol 180: 1170-1178, 2012.
12. Blake A, Dragan M, Tirona RG, Hardy DB, Brackstone M, Tuck AB, Babwah AV and Bhattacharya M: G protein-coupled KiSS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance. Sci Rep 7: 46525, 2017.
13. Schmid K, Wang X, Hafel A, Sieghart W, Peck-Radosavljevic M, Bodingbauer M, Rausch-Ronchaub S and Wrba F: KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: An immunohistochemical study. Virchows Archiv 450: 143-149, 2007.
14. Rajkumar SV: Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88: 226-235, 2013.
15. Hideshima T, Richardson P and Anderson KC: Novel therapeutic approaches for multiple myeloma. Immunol Rev 194: 164-176, 2003.
16. Gay F and Palumbo A: Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol 27: 43-52, 2010.
17. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG and Anderson K: Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9: 135-143, 2012.
18. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Wier SV, Tiedemann R, Shi CX, Sebag M, et al: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144, 2007.

19. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007.

20. Berenson JR, Ma HM and Vescio R: The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28: 626-633, 2001.

21. Landowski TH, Olashaw NE, Agrawal D and Dalton WS: Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 22: 2417-2421, 2003.

22. Umezawa K: Possible role of peritoneal NF-kappaB in peripheral inflammation and cancer: Lessons from the inhibitor NF-kappaB (Review). Biomed Pharmacother 65: 252-259, 2011.

23. Tatetsu H, Okuno Y, Nakamura M, Matsuno F, Sonoki T, Taniguchi I, Uneda S, Umezawa K, Mitsuwa H and Hata H: Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. Mol Cancer Ther 4: 1114-1120, 2005.

24. Horie R, Watanabe M, Okamura T, Taira M, Shoda M, Motoji T, Utsunomiya A, Watanabe H, Hitoshihara M and Umezawa K: DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20: 582-590, 2006.

25. Suzuki Y, Sugiyama C, Ohno O and Umezawa K: Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-kappaB inhibitor. Tetrahedron 60: 7061-7066, 2004.

26. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K and Alkan S: Analysis of expression of nuclear factor B (NF-kappa B) in multiple myeloma: Down-regulation of NF-kappa B induces apoptosis. Br J Haematol 115: 279-286, 2001.